NCT00831636 - A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

November 30, 2009

Study Completion Date

April 30, 2010

Conditions

Ovarian Cancer

Interventions

DRUG

CP-4055

D1-5 and D8(+2)-12(+2) q4w

DRUG

CP-4055

IV administration day 1-5 and day 8-12 in a 4 week schedule

Trial Locations (5)

U.Z. Gasthuisberg, Gynecologic Oncology, Herestraat 49, Leuven

Medical Oncology C, National Cancer Institute, Centro di Riferimento Oncologico, Aviano (PN)

Medical Oncology, Fatebenefratelli Hospital, Isola Tiberina, Rome

Medical Oncology B, National Cancer Institute, Via Mariano Semmola, Naples

Department of Oncology, Catholic University of the Sacred Heart, Rome